Introduction
Growth factors regulate cellular proliferation and differentiation and are important in initiating and maintaining neoplastic transformation. Cancer cells exhibit a decreased requirement for exogenous growth factors compared with normal cells, due in part to the ability of tumor cells to synthesize growth factors that can regulate their proliferation through autocrine and paracrine mechanisms by activating specific cell membrane receptors [1] . Growth factors of the epidermal growth factor (EGF) gene family, such as transforming growth factor a (TGFa), are potent mitogens for several human epithelial cell types including breast, colon, ovary, kidney, prostate and lung, and have been implicated in cancer development and progression [1] . TGFa binds to the extracellular domain of the EGF receptor (EGFR) and activates its intracellular tyrosine kinase domain [1] . The EGFR is a 170 kDa transmembrane glycoprotein with an external binding domain and an intracellular tyrosine kinase domain [1] . Ligand binding induces dimerization of the EGFR and its autophosphorylation on several tyrosine residues in the intracellular domain, creating a series of high-affinity binding sites for various transducing molecules that are involved in transmitting the mitogenic signaling mainly through the ras/raf/MAPK pathway [2] , Moreover, increasingly evidence has been provided of a functional and structural connection between the EGFR and the other three known EGFRrelated growth factor receptors, erbB-2, erbB-3 and erbB-4 [1] . In fact, a complex mitogenic and differentiation signaling network has been elucidated in both normal and cancer cells depending upon the binding of the various EGF-like ligands and the subsequent preferential activation of different heterodimers between the EGFR and the EGFR-related receptors [1, [3] [4] [5] . Enhanced expression of TGFa and/or EGFR has been detected in the majority of human carcinomas and has been associated with poor prognosis in several human tumor types, such as breast cancer [1] . TGFa and EGFR overexpression have also been found in human cancer cell lines that are resistant to different cytotoxic drugs [6] .
The cAMP-dependent protein kinase (PKA) is an intracellular enzyme with serine-threonine kinase activity that plays a key role in cell growth and differentiation and is present in mammalian cells in two distinct isoforms, defined PKAI and PKAII. PKAI and PKAII share identical catalytic (C) subunits, but differ in the regulatory (R) subunits (termed RI in PKAI and RII in PKAII, respectively) [7] . The synthesis of RI and RII and the relative abundance of PKAI and PKAII isoforms are differentially regulated during differentiation, cell growth and neoplastic transformation [7] . Several features suggest that PKAI and PKAII have different functions in the control of cell growth and differentiation. Predominant expression of PKAII is found in normal nonproliferating tissues and is associated with inhibition of mitogenic signaling and cell growth in cancer cells, and to RARP-related cell growth arrest following treatment with retinoids [7, 8] .
In contrast, PKAI and/or its regulatory subunit RIa are generally overexpressed in human cancer cell lines and in primary tumors and are induced following transformation by certain oncogenes, such as ras [7] . Detection of PKAI/RIa overexpression correlates with worse clinical and/or pathological features in colon, breast and ovarian cancer [9] [10] [11] . RIa has also been identified as the tissue extinguisher of differentiation (TSE1), an inhibitor of the expression of several genes related to cell differentiation [12] , or, fused to the ret oncogene, to form the PTC2 transforming sequence identified in human papillary thyroid carcinomas [13] . PKAI can also be transiently induced in normal cells following exposure to specific mitogenic stimuli, as will be discussed further [7] . Another important difference between PKAI and PKAII consists in their distinct subcellular locations, mainly due to anchoring proteins (AKAPs) able to target them close to specific sites [14] .
In the past decade, a large body of experimental evidence has disclosed a functional link between neo-plastic transformation involving theTGFa-EGFR autocrine pathway and PKAI expression and activity. This review outlines the biological relevance of the interactions between the activated EGFR and PKAI and the therapeutic potential of the blockade of these pathways, including the results of recent preclinical and clinical studies.
PKAI expression is coupled to EGFR-dependent and rasdependent transformation
Several studies conducted in murine as well in human cell models have shown cross-talk among PKAI, TGFaactivated EGFR and ras in neoplastic transformation. Increased expression of RIa and/or PKAI and decrease of PKAII are early events occurring during transformation induced by TGFa and/or ras [15, 16] . In contrast, treatment with selective inhibitors of PKAI, such as 8-Cl-cAMP or antisense oligonucleotides, causes early inhibition of TGFa and/or ras expression, which anticipates cell growth inhibition [15] [16] [17] . Moreover, in human breast and ovarian cancer cells the inhibition of PKAI expression by antisense oligonucleotides is accompanied by decreases in EGFR expression and MAP kinase signalling and by growth arrest [18] . Reciprocally, inhibition of EGFR expression by transfection of an antisense EGFR plasmid vector is accompanied by the selective down-regulation of PKAI expression and signaling and by growth inhibition [18, 19] . Finally, in another study, growth inhibition by 8-Cl-cAMP was associated with the block of EGF-stimulated activation of MAPK, ERK-1 and ERK-2 [20] .
PKAI is physiologically involved in EGFR-dependent mitogenic signaling
A link between PKA and EGFR-and/or ras has also been demonstrated in several normal cell systems. In nontransformed MCF-10A human mammary epithelial cells, which strictly depend on EGF or TGFafor cell growth, induction of PKAI anticipates cell entry into S phase after addition of EGF or TGFa. Inhibition of PKAI abrogates the effect of EGF or TGFa, arresting the cells in late Gl phase [21] . The same event occurs in rat thyroid cells stimulated by TSH [22] or in activated lymphocytes [23, 24] , Moreover, constitutive overexpression of PKAI in MCF-10A cells overcomes the requirement for EGF or TGFa for cell entry into S phase and induces a permanent activation of MAPK [21] . We have demonstrated that PKAI and the EGFR are not only functionally linked but have a direct structural interaction. In fact, PKAI participates in a macromolecular complex with the activated EGFR, through the binding of its RIa subunit to the SH3 domain(s) of Grb2 adaptor protein, thus allowing the recruitment of PKAI holoenzyme to the activated EGF-R and the propagation of the mitogenic signaling [25] . Taken together these data suggest that PKAI allows the mitogenic signaling by growth factors of the EGF family in human mammary epithelial cells.
We hypothesize that a possible mechanism by which PKAI conveys mitogenic signaling may consist in the titration of the available C subunit. This event would prevent the formation of a PKAII (3 enzyme and the PKAII-dependent phosphorylation of key targets, eventually leading to cell growth arrest. To support this hypothesis, a recent study has shown that the activated C subunit is able to phosphorylate the EGFR inhibiting its tyrosine kinase activity and signal transduction [26] .
EGFR and PKAI as targets for cancer therapy

Inhibition of EGFR
Since experimental and clinical studies have provided evidence for a TGFa-mediated autocrine growth stimulatory pathway in a variety of human cancers, the blockade of the TGFa-EGFR pathway has been proposed as a therapeutic modality [27] . Several pharmacologic and biologic approaches have been developed to block EGFR activation and/or function in cancer cells. In the past 10 years, various anti-EGFR blocking monoclonal antibodies (MAb), recombinant proteins containing TGFa or EGF fused to toxins, and tyrosine kinase inhibitors have been generated and characterized for their biologic and potentially therapeutic properties [28] [29] [30] [31] [32] [33] . One of these agents, MAb C225, a chimeric humanmouse IgGi MAb, has recently entered phase II and phase III clinical evaluation in cancer patients [27, [34] [35] [36] . Several compounds recently developed are able to block the ligand-induced activation of the EGFR tyrosine kinase and, in some cases, to a lesser extent, that of the closely related erbY$-2 receptor [37] . Among these, various quinazoline-derived agents have been synthesized and tested as anticancer agents in vitro and in preclinical models [37] . ZD-1839 (Iressa™), an anilinoquinazoline, is an orally active, selective inhibitor of the EGFR tyrosine kinase, which is currently under clinical evaluation in early clinical trials in cancer patients [38, 39] . Furthermore, a large body of experimental evidence has been recently accumulated on the enhanced antitumor activity of some chemotherapy agents, such as doxorubicin, cisplatin, paclitaxel, or topotecan, in combination with MAbs that selectively block the EGFR [40] [41] [42] . Similarly, the combined treatment of mice bearing well established human tumor xenografts with ZD-1839 and with cytotoxic drugs, such as paclitaxel, docetaxel, cisplatin, topotecan and raltitrexed, significantly increases the antitumor activity of these drugs [43, 44] .
Inhibition of PKAI
Inhibition of PKAI can be obtained by an indirect approach, e.g., the use of agents such as phosphodiesterase inhibitors, which raise the intracellular cAMP up to levels able to activate the PKAII and, in turn, suppress PKAI. A more feasible and direct approach is based either on the use of site-selective cAMP analogues (SSA), such as 8-Cl-cAMP, which is able to induce degradation of the RIa protein and upregulation, at transcriptional level, of RII expression [7, 45] , or on the use of specific RIoc antisense oligonucleotides.
8-Cl-cAMP causes cell growth inhibition and differentiation in a wide variety of human cancer types in vitro and in vivo [7, 46] . These effects are accompanied by time-dependent and dose-dependent inhibition of expression of different oncogenes and growth factors, including ras, myc, TGFa, basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) [15] [16] [17] 47] . Interestingly, 8-Cl-cAMP also causes a partial inhibition of erbft-2 expression, suggesting that this receptor may involve, either indirectly or through the interaction with the EGFR, PKAI for mitogenic signaling [17] . Moreover, 8-Cl-cAMP is able to revert multidrug resistance (MDR) in a variety of MDR cancer cell lines restoring their sensitivity to cytotoxic drugs [48] .
Three phase I clinical trials with 8-Cl-cAMP administered by different schedules have been conducted in cancer patients refractory to standard therapies [49] [50] [51] . Complexively, 56 patients were treated and the majority of them received multiple cycles of treatment. Reversible hypercalcemia, due to parathyroid hormone-like effect [52] , in all the studies, and renal toxicity, experienced with higher doses of drug in one study, were the doselimiting toxicities. Importantly, no hematologic toxicity was observed in the three studies. In this regard, in a previous study conducted on samples from acute myeloid leukemia patients, we have demonstrated that 8-C1-cAMP inhibits only the growth of leukemic blasts, but not that of normal bone marrow progenitors [53] . Moreover, biological responses, including increase in percent and cytotoxic activity of NK cells, and drug activity were reported [49, 51] . In our study we observed a partial response in a patient with colon cancer, and a stable disease in two patients with colon cancer and in one patient with non-small-cell lung cancer (up to 15 months), all with progressive disease before treatment [49] . In another study, one patient with thymoma and one with colon cancer, both with progressive disease, remained stable for 40 months and for 4 months, respectively [51] . The recommended doses for phase II evaluation resulting from these 2 studies were 0.1 mg/kg/hr for 5 days/week for 2 weeks every 21 days [49] and 0.15 mg/kg/hr for 3 days/week for 3 weeks every 28 days [51] , respectively. Both studies show that 8-Cl-cAMP can be safely administered to cancer patients at doses that achieve plasma concentrations within the potential therapeutic range for growth inhibition and show biologic activity. Recently, we and others have also shown that 8-Cl-cAMP is able to cooperate with a variety of cytotoxic drugs, including taxanes, toward growth inhibition of human cancer cells in vitro [54, 55] and in vivo [54] .
A more direct approach to inhibiting the synthesis and function of PKAI has been developed by the use of antisense oligonucleotides targeted against the 5' coding sequence of the human RIa mRNA. Treatment with either unmodified or phosphorothioate (PS) antisense RIa oligonucleotides suppresses RIa production and determines inhibition of in vitro proliferation in various human cancer cells in vitro and in vivo [56] [57] [58] . To further improve the therapeutic potential of PS-antisense oligonucleotides a series of novel mixed-backbone oligonucleotides (MBOs) targeted against RIa have been synthesized [59] . These new compounds have shown a significant reduction of side-effects and good pharmacokinetic profiles which render them particularly suitable for in vivo applications [60] . An MBO antisense RIa has shown a marked antitumor effect in vivo in nude mice bearing human cancer xenografts and a cooperative effect with different cytotoxic drugs, including taxanes [61] . More recently, in a model of human breast cells, we have shown that c-erbB-2, but not c-Ha-ras, overexpression reduce sensitivity to taxanes and that the MBO antisense RIa is able to revert such resistance [62] . These results further support the hypothesis that erbB-2 may partly involve PKAI in transducing mitogenic signals.
A novel MBO antisense RIa given by oral route shows a cooperative effect with taxanes toward tumor growth, induction of apoptosis and inhibition of angiogenesis and of different growth factors of the EGF family [63] . This latter compound (GEM 231™), given by i.v. administration has successfully completed a phase I study in cancer patients with minor toxicity [64] . GEM 231™ was administered i.v. in a two-hour infusion, twice weekly. Cumulative toxicity after four weeks was seen with a reversible grade 3 increase in transaminases in three of six patients at 240 mg/m 2 and in three of three patients at 360 mg/m 2 . Other toxicities were negligible. Therefore, 240 mg/m 2 for four-week treatment has been considered the recommended dose for further clinical evaluation [64] . This dose and schedule has been also selected for a clinical study in combination withTaxol.
Combined blockade of EGFR and PKAI
The pleiotropic functions of EGFR and PKAI pathways, as well as the experimental evidence of a functional link between these two signaling systems in neoplastic transformation has prompted studies to evaluate whether the double blockade of EGFR and PKAI may have an antiproliferative effect in human cancer cells and may improve the antitumor activity of either blockade alone. We have first evaluted the growth inhibitory effects of the combined treatment with the anti-EGFR MAb 528 and 8-Cl-cAMP on several human colon and breast cancer cell lines that secrete TGFa and express functional EGFRs. We have demonstrated a supradditive growth inhibitory effect with a three-fold to five-fold reduction in the 8-Cl-cAMP IC 50 when used in combination with low noninhibitory doses of MAb 528 [65] . We have next demonstrated that the combination of the humanized chimeric anti-EGFR MAb C225 and 8-C1-cAMP is a highly effective anticancer treatment regimen in vivo, using human GEO colon carcinoma xenografts as a model [66] . Treatment with low doses of MAb C225 and 8-Cl-cAMP for five weeks resulted in a long-term suppression of GEO tumor growth, since tumors resume their growth only after approximately eight weeks from cessation of the treatment [66] . This effect was accompanied by a statistically significant benefit in animal survival in the group treated with both agents compared with the groups treated with a single agent. No such effect could be obtained increasing the doses of each single agent alone. The anticancer activity of MAb C225 and 8-Cl-cAMP in combination was also accompanied by the suppression of autocrine growth factors, such as TGFo, AR and CRIPTO, and of paracrine angiogenic growth factors, such as VEGF and bFGF, as detected by histochemistry on tumor specimen [66] . These effects resulted in a strong inhibition in tumorinduced host neoangiogenesis. Finally, MAb C225 and 8-Cl-cAMP treatments were well tolerated since no signs of toxicity were observed in any treatment group.
We have also demonstrated a similar cooperative antitumor effect by the anti-EGFR MAbs and a MBO antisense RIa in combination. In an attempt to develop a model of selective biologic therapy of human renal cancer that could be translated and explored in a clinical setting, we have tested the antiproliferative activity of these agents in several human renal cancer cell lines [67] . In fact, both EGFR and PKAI are overexpressed in 70% to 100% human renal cancers. A marked increase of the antiproliferative activity in vitro and in vivo was obtained by combining MAb C225 and MBO antisense RIa. The two agents used in combination caused regression of the renal cancer, whereas no single agent, even at higher doses, was able to do so. These results suggest that the cooperative effect obtained by the combined blockade of EGFR and PKAI is not due to a dosedependent activity of each single agent, but rather to the simultaneous inhibition of two key signaling systems which share several common pathways but also involve other mitogenic molecules. A further potential mechanism by which MBO antisense RIa exherts its supradditive antiproliferative effect with MAb C225 could be by inducing programmed cell death. In fact, we observed apoptosis in various renal cancer cell lines treated with MAb C225 and MBO antisense RIa [67] . The combined blockade of the EGFR-mediated autocrine pathway and of PKAI activity, which is required to traverse the cell cycle from Gi to S phases, could render cancer cells unable to overcome this double interference with the mitogenic signaling and thereby become more susceptible to apoptosis. In this respect, a three-week treatment of nude mice bearing established human renal ACHN xenografts with MAb C225 or with MBO antisense RIa had a cytostatic growth inhibitory effect with a reduction in tumor growth rate compared with control, whereas the combined treatment with both agents for the same period and with the same doses induced tumor regression in the combination treatment group, with no evidence of tumor in 2 out of 10 mice [67] . Furthermore, we have recently demonstrated that the MBO antisense RIa inhibits the growth of human breast ZR-75-1 cancer cells, exhibits a synergistic growth inhibitory activity with docetaxel or MAb C225 and, remarkably, an even higher degree of cooperativity can be obtained when the three agents are used together at suboptimal doses [68] . In the same study, we have shown that the MBO antisense RIa, as well as docetaxel and MAb C225, induces BCL-2 phosphorylation and that the cooperative antiproliferative effect of the three agents together results in increase of phosphorylated BCL-2 protein and apoptosis. Recently, roles for PKA in 5CL-2-dependent apoptotic pathway and in taxane-dependent modulation of BCL-2 function have been reported [69, 70] . These data along with the marked and mutual cooperativity between PKAI inhibitors, EGFR antagonists and taxanes toward apoptosis may provide an explanation for the sustained antitumor effect observed in animals treated with these agents in combination, outlasting treatment withdrawal.
Conclusions
The inhibition of molecular targets relevant for mitogenic signaling represents a new challenging opportunity in cancer treatment [71] . PKAI and EGFR have pleiotropic signaling functions and share several common partners in the signal transduction machinery. An interaction between EGFR and PKAI occurs through direct binding of RIa subunit to Grb2 adaptor protein. Therefore, PKAI seems to function downstream to EGFR and ras and experimental evidence suggests that PKAI is acting upstream to the MAPK pathway. Moreover, the c-erftB-2 signaling pathway, either directly or by its interaction with EGFR, seems to involve PKA. The combined interference with EGFR-dependent and PKAIdependent pathways obtained with agents like anti-EGFR blocking MAbs, selective EGFR-tyrosine kinase inhibitors, cAMP analogues and novel antisense MBOs, results in a cooperative antiproliferative effect on human cancer cells in vitro and in vivo. All the selective inhibitors of intracellular mitogenic signaling described in this report have different mechanisms of action compared with those of cytotoxic agents and have demonstrated a cooperative growth inhibitory effect when used in combination with several conventional cytotoxic drugs in a large series of human cancer cell lines in vitro and in vivo. This property may have important clinical implications, since it allows us to enhance anticancer activity of maximum tolerated doses of cytotoxic drugs and to obtain a more selective and protracted control of tumor growth, instead of increasing chemotherapy doses to supertoxic levels [72] . The induction of apoptosis obtained with the inhibitors of PKAI and EGFR in combination with taxanes suggest an interplay among these different pathways, further increasing the therapeutic opportunities provided by their selective targeting. Moreover, the suppression of growth factors involved in cell growth and angiogenesis could lead to a status of tumor dormancy [73] , contributing to long-term control of cancer cell growth and spreading with negligible toxicity.
Therefore, the combination of selective anti-EGFR and anti-PKAI agents following or together with chemotherapy represents a novel therapeutic strategy that could be investigated in cancer patients, since all the above inhibitors are currently under evaluation in clinical trials.
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